~~<i id='539CF87CB8'><strike id='539CF87CB8'><tt id='539CF87CB8'><pre id='539CF87CB8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

focus

author：focus 2025-09-06 04:50:55 - browse：9

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

hotspot

focus

hotspot

leisure time

BRENDANSMIALOWSKI/AFP/GettyImages“Allofyourmedicalandsurgicalexpenseswillbepaidbyyourrecipient’sinsu

WSS

Chronically ill young patients struggle to find fertility info

Medicare slashes safety net hospital payments by nearly $1 billion

UCB departs biotech trade group BIO

How I helped Pfizer think through the ethics of Viagra

The cancer stories no one wants to hear

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

leisure time

focus

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

FDA approves Sage Therapeutics’ rapid

State Dept. review finds Biden bears some blame for Afghanistan failures

Chris Christie meets with Zelenskyy during Ukraine trip

Trump demands the U.S. pay no more for drugs than other countries … again

How I helped Pfizer think through the ethics of Viagra

Hollywood unions extend contract negotiations for actors

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

The high cost of giving birth even with insurance

3 trends to watch in health tech's hiring outlook for 2024

hotspot

Study links childhood stress with decline in older age

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Late stage cancers on the rise after pandemic delayed screenings

Personalized medicine goes far beyond genetics

A controversial new treatment promises to make little people taller

hotspot

focus

hotspot

leisure time